Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development.


Journal

The Biochemical journal
ISSN: 1470-8728
Titre abrégé: Biochem J
Pays: England
ID NLM: 2984726R

Informations de publication

Date de publication:
28 10 2022
Historique:
received: 01 07 2022
revised: 03 10 2022
accepted: 05 10 2022
entrez: 28 10 2022
pubmed: 29 10 2022
medline: 2 11 2022
Statut: ppublish

Résumé

Through activation of immune cells, the immune system is responsible for identifying and destroying infected or otherwise damaged cells including tumorigenic cells that can be recognized as foreign, thus maintaining homeostasis. However, tumor cells have evolved several mechanisms to avoid immune cell detection and killing, resulting in tumor growth and progression. In the tumor microenvironment, tumor infiltrating immune cells are inactivated by soluble factors or tumor promoting conditions and lose their effects on tumor cells. Analysis of signaling and crosstalk between immune cells and tumor cells have helped us to understand in more detail the mechanisms of tumor immune evasion and this forms basis for drug development strategies in the area of cancer immunotherapy. In this review, we will summarize the dominant signaling networks involved in immune escape and describe the status of development of therapeutic strategies to target tumor immune evasion mechanisms with focus on how the tumor microenvironment interacts with T cells.

Identifiants

pubmed: 36305711
pii: 232000
doi: 10.1042/BCJ20210233
doi:

Types de publication

Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2219-2260

Informations de copyright

© 2022 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Auteurs

Qian Wei (Q)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, N-0424 Oslo Norway and K.G. Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, N-0317 Oslo Norway.

Kjetil Taskén (K)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, N-0424 Oslo Norway and K.G. Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, N-0317 Oslo Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH